2 recruiting, 1 active not recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
Follow Avalyn Pharma Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF AP02, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | Avalyn Pharma Inc. | 160 | 2026-03-10 | 2026-10-15 |
| An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) AP01 - Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | Avalyn Pharma Inc. | 340 | 2025-04-17 | 2026-10-02 |
| A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis AP01, Placebo - Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 2 | Active not recruiting | Avalyn Pharma Inc. | 398 | 2024-04-03 | 2026-10-16 |
Idiopathic Pulmonary Fibrosis (2) · Alveolitis, Extrinsic Allergic (1) · Lung Diseases, Interstitial (1) · Pulmonary Fibrosis (1)
Australia (3) · Canada (3) · Germany (3) · New Zealand (3) · Spain (3) · United Kingdom (3) · Argentina (2) · France (2) · Italy (2) · Netherlands (2) · Poland (2) · Turkey (Türkiye) (2) · United States (2) · Belgium (1) · Czechia (1)